Summary
Twenty-eight hypertensive patients on renal replacement therapy (HD, HF, PD) were treated with verapamil (Isoptin RR-slow release) in an open label study. Blood pressure was satisfactorily reduced in 21 patients (84%). Due to adverse reactions the treatment had to be discontinued in 4 patients. Verapamil clearances were calculated according to different dialysis methods. No changes in dose or mode of application of verapamil were necessary using any mode of renal replacement therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mooy J (1985) Pharmacokinetics of verapamil in patients with renal failure. Eur J Clin Pharmacol 28: 405–410
Hanyok JJ (1988) An evaluation of the pharmacokinetics, pharmacodynamics and dialyzability of verapamil in chronic hemodialysis patients. J Clin Pharmacol 28: 831–838
Kuwada M (1981) Simultaneous determination of verapamil and its seven metabolites by high-performance liquid chromatography. J Chromatogr 222: 507–511
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beyerlein, C., Csaszar, G., Hollmann, M. et al. Verapamil in antihypertensive treatment of patients on renal replacement therapy — clinical implications and pharmacokinetics. Eur J Clin Pharmacol 39 (Suppl 1), S35–S37 (1990). https://doi.org/10.1007/BF03216273
Issue Date:
DOI: https://doi.org/10.1007/BF03216273